|
[Related PubMed/MEDLINE]
Total Number of Papers: 70
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. |
CEPAC, HIV, HOPE, ICC, ICER, individual benefit, MSM, PrEP, PWID |
| 2 |
2020 |
Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa. |
CT, HT, IC, ICER, QC, R e |
| 3 |
2020 |
Strengthening Existing Laboratory-Based Systems vs. Investing in Point-of-Care Assays for Early Infant Diagnosis of HIV: A Model-Based Cost-Effectiveness Analysis. |
ART, EID, ICERs, LAB, LE, POC, POC, S-LAB |
| 4 |
2020 |
The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. |
HIV, ICER, MSM, MSM, PrEP, PWID |
| 5 |
2020 |
The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador. |
HPV |
| 6 |
2019 |
Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis. |
VIA |
| 7 |
2019 |
Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Cote d'Ivoire: A model-based analysis. |
ICERs, PWH |
| 8 |
2019 |
Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. |
ICER |
| 9 |
2019 |
Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector. |
DMCs, ICERs, TB, Truenat DMC |
| 10 |
2018 |
Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial. |
ASPIRE, HPV, ICERs, VIA |
| 11 |
2018 |
Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study. |
ART, DAA, HCV, ICERs, NSP, OST, PWID |
| 12 |
2018 |
The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. |
ART, CEPAC, DTG, EFV, ICERs, SOC, TDF |
| 13 |
2018 |
The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. |
CEPAC, GDP, ICER, MSM, PrEP, SOC, TGW, USD |
| 14 |
2018 |
The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. |
AYA |
| 15 |
2018 |
Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness. |
HIV, ICER, PY, UNAIDS, VCT |
| 16 |
2017 |
Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. |
ICER, MRI, RRM |
| 17 |
2017 |
Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting. |
ICERs |
| 18 |
2017 |
Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua. |
HPV, ICER, Pap, VIA |
| 19 |
2017 |
Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon. |
CC, GDP |
| 20 |
2017 |
Societal costs and effects of implementing population-based mammography screening in Greenland. |
QALY |
| 21 |
2017 |
The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations. |
CLIN, LAB-CD4, POC-CD4 |
| 22 |
2017 |
To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings. |
--- |
| 23 |
2015 |
Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention. |
ICERs, NCCN, SQ |
| 24 |
2014 |
Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Cote d'Ivoire. |
ART, ICERs |
| 25 |
2014 |
Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. |
CEPAC-I, GDP, ICER |
| 26 |
2014 |
The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis. |
ART, ICERs, LAB-CD4, POC-CD4 |
| 27 |
2013 |
Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. |
ART, ICERs, PY |
| 28 |
2013 |
Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. |
HIV, LE, sdNVP, WHO |
| 29 |
2013 |
Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. |
DALYs, HPV |
| 30 |
2013 |
The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. |
ART, HIV, WT |
| 31 |
2012 |
Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country. |
HAART |
| 32 |
2012 |
Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. |
HPV, VIA |
| 33 |
2012 |
Earlier initialization of highly active antiretroviral therapy is associated with long-term survival and is cost-effective: findings from a deterministic model of a 10-year Ugandan cohort. |
ICER |
| 34 |
2012 |
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. |
ART, CEPAC |
| 35 |
2012 |
Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. |
--- |
| 36 |
2012 |
Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. |
GDP, HPV |
| 37 |
2012 |
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. |
ART, ICERs, TB |
| 38 |
2012 |
The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. |
ICER, IPT, TB |
| 39 |
2011 |
Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. |
ART |
| 40 |
2011 |
Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. |
ASCUS, HPV |
| 41 |
2010 |
Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis. |
EmOC, GDP |
| 42 |
2010 |
Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. |
HC2, HPV |
| 43 |
2010 |
Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. |
TB |
| 44 |
2010 |
Cost-effectiveness of human papillomavirus vaccination and screening in Spain. |
HPV |
| 45 |
2010 |
Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. |
ART, WHO |
| 46 |
2009 |
Cost effectiveness of a test to detect metastases for endometrial cancer. |
ICER, SEER |
| 47 |
2009 |
Cost-effectiveness analysis of annual screening strategies for endometrial cancer. |
BMI, ICER |
| 48 |
2009 |
Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. |
--- |
| 49 |
2008 |
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? |
--- |
| 50 |
2007 |
Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. |
HCV, HIV |
| 51 |
2007 |
Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. |
CR, HDR, LDR, PET/CT |
| 52 |
2007 |
The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. |
ART, OECS |
| 53 |
2007 |
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. |
HPV |
| 54 |
2006 |
Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. |
--- |
| 55 |
2004 |
Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. |
--- |
| 56 |
2003 |
An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. |
HNPCC |
| 57 |
2003 |
[Current framework of biotechnology products according to the available pharmacoeconomic studies]. |
--- |
| 58 |
2002 |
Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. |
ASCUS, HPV, QALYs |
| 59 |
2001 |
Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. |
DVI, HPV |
| 60 |
2000 |
A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. |
--- |
| 61 |
1999 |
Screening for malignant melanoma: A cost-effectiveness analysis. |
--- |
| 62 |
1999 |
Selective preoperative cardiac screening improves five-year survival in patients undergoing major vascular surgery: a cost-effectiveness analysis. |
--- |
| 63 |
1999 |
Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review. |
NSCLC |
| 64 |
1998 |
Cost effectiveness of coronary heart disease prevention strategies in adults. |
CHD, QALY |
| 65 |
1997 |
The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. |
--- |
| 66 |
1996 |
Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty. |
DVT, LMWH, PE, THA, UFH |
| 67 |
1996 |
Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. |
PCP |
| 68 |
1995 |
Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction. |
PTCA |
| 69 |
1995 |
Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. |
EP, ICD |
| 70 |
1993 |
Cost-effectiveness of a tobacco 'quit and win' contest in Sweden. |
--- |
|
A Search Service for Abbreviation / Long Form
